tiprankstipranks
Knight Therapeutics Shareholders Back Directors and Auditors
Company Announcements

Knight Therapeutics Shareholders Back Directors and Auditors

Knight Therapeutics (TSE:GUD) has released an update.

Don't Miss our Black Friday Offers:

Knight Therapeutics Inc. successfully concluded its Annual General Meeting, with all director nominees from the Management Information Circular being elected with high approval rates. Additionally, Ernst & Young LLP were appointed as external auditors with overwhelming shareholder support, and a resolution to renew unallocated rights under the Omnibus Equity Incentive Plan was approved by a significant majority.

For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyKnight Therapeutics price target lowered to C$7.50 from C$8 at Raymond James
TheFlyKnight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel
TipRanks Auto-Generated NewsdeskKnight Therapeutics Reports Q3 2024 Financial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App